Knightsbridge Asset Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Knightsbridge Asset Management’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-13,542	Closed	-$25K	–	140
2023 Q1	$25K	Buy	+13,542	New	+$16.8K	﹤0.01%	128

Other funds holding JNCE

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Knightsbridge Asset Management's JNCE Position: Q2 2023 in Review

Knightsbridge Asset Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 13,542 shares — an estimated $25K sold.

Knightsbridge Asset Management first reported a position in JNCE in Q1 2023 and held it in 1 quarter. The position peaked at $25K in Q1 2023. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

Knightsbridge Asset Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Knightsbridge Asset Management sold 13,542 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $25K.
Knightsbridge Asset Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
Knightsbridge Asset Management's Jounce Therapeutics, Inc. Common Stock position peaked at $25K in Q1 2023.
1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Knightsbridge Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.